The roles of neutral sphingomyelinases in neurological pathologies

Neurochemical Research

Volumn 37, Issue 6, 2012, Pages 1137-1149

  Horres, Charles R ^a   Hannun, Yusuf A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ceramide; Sphingolipids; Sphingomyelinases; Sphingosine

Indexed keywords

AMYLOID BETA PROTEIN; CERAMIDE; FUMONISIN B1; GLYCOPROTEIN GP 120; NEUTRAL SPHINGOMYELINASE 1; NEUTRAL SPHINGOMYELINASE 3; S NITROSOGLUTATHIONE; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; APOPTOSIS; BRAIN ATHEROSCLEROSIS; BRAIN CANCER; BRAIN EMBOLISM; BRAIN ISCHEMIA; BRAIN TISSUE; CATALYSIS; CHONDRODYSPLASIA; DISEASE MARKER; DRUG MECHANISM; DWARFISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME METABOLISM; HIV ASSOCIATED DEMENTIA; HUMAN; MAMMAL; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM; NEUROPATHOLOGY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPECIES COMPARISON;

AGING; AIDS ARTERITIS, CENTRAL NERVOUS SYSTEM; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; BRAIN CHEMISTRY; CERAMIDES; ENCEPHALITIS; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNESIUM; MICE; MICE, KNOCKOUT; NEOPLASMS; NEURODEGENERATIVE DISEASES; RATS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; THROMBOEMBOLISM;

EID: 84862861650     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0692-y     Document Type: Review

References (142)

1. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9:139-150 (Pubitemid 351158911)
2. Luberto C, Kraveka JM, Hannun YA (2002) Ceramide regulation of apoptosis versus differentiation: a walk on a fine line. Lessons from neurobiology. Neurochem Res 27:609-617
3. Jones I, He X, Katouzian F, Darroch PI, Schuchman EH (2008) Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models. Mol Genet Metab 95:152-162
4. Wu BX, Clarke CJ, Hannun YA (2010) Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses. Neuromol Med 12:320-330
5. Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W (1998) Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc Natl Acad Sci USA 95:3638-3643 (Pubitemid 28173180)
6. Tomiuk S, Zumbansen M, Stoffel W (2000) Characterization and subcellular localization of murine and human magnesiumdependent neutral sphingomyelinase. J Biol Chem 275:5710-5717 (Pubitemid 30115212)
7. Rodrigues-Lima F, Fensome AC, Josephs M, Evans J, Veldman RJ, Katan M (2000) Structural requirements for catalysis and membrane targeting of mammalian enzymes with neutral sphingomyelinase and lysophospholipid phospholipase C activities. Analysis by chemical modification and site-directed mutagenesis. J Biol Chem 275:28316-28325
8. Tepper AD, Ruurs P, Borst J, van Blitterswijk WJ (2001) Effect of overexpression of a neutral sphingomyelinase on CD95-induced ceramide production and apoptosis. Biochem Biophys Res Commun 280:634-639 (Pubitemid 32924477)
9. Zumbansen M, Stoffel W (2002) Neutral sphingomyelinase 1 deficiency in the mouse causes no lipid storage disease. Mol Cell Biol 22:3633-3638 (Pubitemid 34525207)
10. Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Krönke M (2006) Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem 281:13784-13793 (Pubitemid 43855294)
11. Corcoran CA, He Q, Ponnusamy S, Ogretmen B, Huang Y, Sheikh MS (2008) Neutral sphingomyelinase-3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies. Mol. Cancer Res 6:795-807
12. Krut et al. (2006) Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem
13. Hofmann K, Tomiuk S, Wolff G, Stoffel W (2000) Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 97:5895-5900 (Pubitemid 30367495)
14. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK (2002) Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 277:41128-41139 (Pubitemid 35215704)
15. Marchesini N (2003) Biochemical properties of mammalian neutral sphingomyelinase2 and its role in sphingolipid metabolism. J Biol Chem 278:13775-13783 (Pubitemid 36799914)
16. Clarke CJ, Cloessner EA, Roddy PL, Hannun YA (2011) Neutral sphingomyelinase 2 (nSMase2) is the primary neutral sphingomyelinase isoform activated by tumour necrosis factor-α in MCF-7 cells. Biochem J 435:381-390
17. Philipp S, Puchert M, Adam-Klages S, Tchikov V, Winoto-Morbach S, Mathieu S, Deerberg A, Kolker L, Marchesini N, Kabelitz D et al (2010) The polycomb group protein EED couples TNF receptor 1 to neutral sphingomyelinase. Proc Natl Acad Sci USA 107:1112-1117
18. Adam-Klages S, Adam D, Wiegmann K, Struve S, Kolanus W, Schneider-Mergener J, Krönke M (1996) FAN, a novel WDrepeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 86:937-947 (Pubitemid 26336798)
19. Tcherkasowa AE, Adam-Klages S, Kruse ML, Wiegmann K, Mathieu S, Kolanus W, Krönke M, Adam D (2002) Interaction with factor associated with neutral sphingomyelinase activation, a WD motif-containing protein, identifies receptor for activated C-kinase 1 as a novel component of the signaling pathways of the p55 TNF receptor. J Immunol 169:5161-5170 (Pubitemid 35217186)
20. Milhas D, Clarke CJ, Idkowiak-Baldys J, Canals D, Hannun YA (2010) Anterograde and retrograde transport of neutral sphingomyelinase-2 between the golgi and the plasma membrane. Biochim Biophys Acta 1801:1361-1374
21. Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA (2004) Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem 279:25101-25111 (Pubitemid 38756759)
22. Devillard R, Galvani S, Thiers JC, Guenet JL, Hannun Y, Bielawski J, Nègre-Salvayre A, Salvayre R, Augé N (2010) Stressinduced sphingolipid signaling: role of type-2 neutral sphingomyelinase in murine cell apoptosis and proliferation. PLoS ONE 5:e9826
23. Stoffel W, Jenke B, Blöck B, Zumbansen M, Koebke J (2005) Neutral sphingomyelinase 2 (smpd3) in the control of postnatal growth and development. Proc Natl Acad Sci USA 102:4554-4559 (Pubitemid 40397150)
24. Stoffel W, Jenke B, Holz B, Binczek E, Günter RH, Knifka J, Koebke J, Niehoff A (2007) Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. Am J Pathol 171:153-161 (Pubitemid 47339235)
25. Aubin I, Adams CP, Opsahl S, Septier D, Bishop CE, Auge N, Salvayre R, Negre-Salvayre A, Goldberg M, Guénet JL et al (2005) A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat Genet 37:803-805 (Pubitemid 41077104)
26. Khavandgar Z, Poirier C, Clarke CJ, Li J, Wang N, McKee MD, Hannun YA, Murshed MA (2011) Cell-autonomous role for neutral sphingomyelinase 2 in bone mineralization. J. Cell Biol. J Cell Biol 194:277-289
27. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101:2070
28. Lightle SA, Oakley JI, Nikolova-Karakashian MN (2000) Activation of sphingolipid turnover and chronic generation of ceramide and sphingosine in liver during aging. Mech Ageing Dev 120:111-125
29. Hernández-Corbacho MJ, Jenkins RW, Clarke CJ, Hannun YA, Obeid LM, Snider AJ, Siskind LJ (2011) Accumulation of longchain glycosphingolipids during aging is prevented by caloric restriction. PLoS One 6:e20411
30. Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23:3262-3271 (Pubitemid 36531967)
31. Ditaranto-Desimone K, Saito M, Tekirian TL, Saito M, Berg M, Dubowchik G, Soreghan B, Thomas S, Marks N, Yang AJ (2003) Neuronal endosomal/lysosomal membrane destabilization activates caspases and induces abnormal accumulation of the lipid secondary messenger ceramide. Brain Res Bull 59:523-531 (Pubitemid 36173608)
32. Jana A, Pahan K (2007) Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol 2:184-193
33. Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, Mattson MP, Geiger JD, Haughey NJ (2009) Tumor necrosis factor-αlpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem 109:1237-1249
34. Lau CG, Zukin RS (2007) NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 8:413-426 (Pubitemid 46789232)
35. Arboleda G, Morales LC, Benítez B, Arboleda H (2009) Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration. Brain Res Rev 59:333-346
36. de la Monte SM, Tong M, Nguyen V, Setshedi M, Longat L, Wands JR (2010) Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis 21:967-984
37. Sawada M, Nakashima S, Banno Y, Yamakawa H, Hayashi K, Takenaka K, Nishimura Y, Sakai N, Nozawa Y (2000) Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ 7:761-772
38. Ganesan V, Perera MN, Colombini D, Datskovskiy D, Chadha K, Colombini M (2010) Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis 15:553-562
39. Crivello NA, Rosenberg IH, Dallal GE, Bielinski D, Joseph JA (2005) Age-related changes in neutral sphingomyelin-specific phospholipase C activity in striatum, hippocampus, and frontal cortex: implication for sensitivity to stress and inflammation. Neurochem Int 47:573-579 (Pubitemid 41437902)
40. Denisova NA, Cantuti-Castelvetri I, Hassan WN, Paulson KE, Joseph JA (2001) Role of membrane lipids in regulation of vulnerability to oxidative stress in PC12 cells: implication for aging. Free Radic Biol Med 30:671-678 (Pubitemid 32280793)
41. Liu H, Wang H, Shenvi S, Hagen TM, Liu R-M (2004) Glutathione metabolism during aging and in Alzheimer disease. Ann N Y Acad Sci 1019:346-349 (Pubitemid 38951332)
42. Toroser D, Sohal RS (2007) Age-associated perturbations in glutathione synthesis in mouse liver. Biochem J 405:583-589 (Pubitemid 47172056)
43. Orr WC, Radyuk SN, Prabhudesai L, Toroser D, Benes JJ, Luchak JM, Mockett RJ, Rebrin I, Hubbard JG, Sohal RS (2005) Overexpression of glutamate-cysteine ligase extends life span in Drosophila melanogaster. J Biol Chem 280:37331-37338 (Pubitemid 41642338)
44. Tabatadze N, Savonenko A, Song H, Bandaru VVR, Chu M, Haughey NJ (2010) Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res 88:2940-2951
45. Jeon HJ, Lee DH, Kang MS, Lee MO, Jung KM, Jung SY, Kim DK (2005) Dopamine release in PC12 cells is mediated by Ca2+-dependent production of ceramide via sphingomyelin pathway. J Neurochem 95:811-820 (Pubitemid 41567172)
46. Hering H, Lin C-C, Shen M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23:3262-3271 (Pubitemid 36531967)
47. Nicol GD (2008) Nerve growth factor, sphingomyelins, and sensitization in sensory neurons. Sheng Li Xue Bao 60:603-604
48. Ito A, Horigome K (1995) Ceramide prevents neuronal programmed cell death induced by nerve growth factor deprivation. J Neurochem 65:463-466
49. Brann AB, Scott R, Neuberger Y, Abulafia D, Boldin S, Fainzilber M, Futerman AH (1999) Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. J Neurosci 19:8199-8208
50. de Chaves EP (2001) Ceramide inhibits axonal growth and nerve growth factor uptake without compromising the viability of sympathetic neurons. J Biol Chem 276:36207-36214
51. Costantini C, Weindruch R, Della Valle G, Puglielli L (2005) A TrkA-to-p75NTR molecular switch activates amyloid β-peptide generation during aging. Biochem J 391:59-67 (Pubitemid 41445476)
52. de la Monte SM, Tong M, Lawton M, Longato L (2009) Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener 4:54
53. Giometto B, Argentiero V, Sanson F, Ongaro G, Tavolato B (1988) Acute-phase proteins in Alzheimer's disease. Eur Neurol 28:30-33 (Pubitemid 18063981)
54. Griffin WS, Stanley LC, Ling C et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611-7615 (Pubitemid 19254506)
55. Fillit H, Ding W, Buee L et al (1991) Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 129:318-320
56. Streit WJ, Mrak RE, Griffin WST (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm 1:14
57. Chakraborty G, Ziemba S, Drivas A, Ledeen RW (1997) Myelin contains neutral sphingomyelinase activity that is stimulated by tumor necrosis factor-alpha. J Neurosci Res 50:466-476 (Pubitemid 27488326)
58. Zhang F, Sha J, Wood TG et al (2008) Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA). Cell Signal 20:844-861
59. Adibhatla RM, Hatcher JF (2008) Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB reports 41:560-567
60. Kriem B, Sponne I, Fifre A et al (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J 19:85-87 (Pubitemid 40069926)
61. Malaplate-Armand C, Florent-Béchard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier J-L, Oster T, Pillot T (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 23:178-189 (Pubitemid 43922461)
62. Rothwell N (2003) Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 17:152-157 (Pubitemid 36434364)
63. Kossmann T, Hans VH, Imhof HG et al (1995) Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 4:311-317
64. Hüll M, Fiebich BL, Lieb K et al (1996) Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol Aging 17:795-800 (Pubitemid 26348882)
65. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, Abner EL, Smith CD, Eldik LJ, Kryscio RJ et al (2011) Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121:571-587
66. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249 (Pubitemid 15053619)
67. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 8:499-509
68. Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, Tupler RG, Wasco W, Hyman BT, Haines JL, Jenkins BJ (1992) Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet 51:273-282
69. Wang G, Silva J, Dasgupta S, Bieberich E (2008) Long-chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia 56:449-456 (Pubitemid 351212953)
70. Jana A, Pahan K (2004) Fibrillar amyloid-β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. J Biol Chem 279(49):51451-51459 (Pubitemid 40017893)
71. Lee J-T, Xu J, Lee J-M, Ku G, Han X, Yang D-I, Chen S, Hsu CY (2004) Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164:123-131 (Pubitemid 38082463)
72. Yang D-I, Yeh C-H, Chen S, Xu J, Hsu CY (2004) Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol Dis 17:99-107 (Pubitemid 39209317)
73. Xuan NT, Shumilina E, Kempe DS, Gulbins E, Lang F (2010) Sphingomyelinase dependent apoptosis of dendritic cells following treatment with amyloid peptides. J Neuroimmunol 219:81-89
74. He X, Huang Y, Li B, Gong C-X, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31:398-408
75. Ittner LM, Götz J (2011) Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12:67-72
76. Zeng C, Lee JT, Chen H, Chen S, Hsu CY, Xu J (2005) Amyloid-β peptide enhances tumor necrosis factor-α-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem 94:703-712 (Pubitemid 41098502)
77. Chen S, Lee JM, Zeng C, Chen H, Hsu CY, Xu J (2006) Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J Neurochem 97:631-640
78. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM (2003) Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278:19777-19783 (Pubitemid 36799164)
79. Alessenko AV, Bugrova AE, Dudnik LB (2004) Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans 32:144-146 (Pubitemid 38283036)
80. Han X, Holtzman DM, McKeel DW Jr, Kelley J, Morris JC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82:809-818
81. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidence-based review) report of the quality standards subcommittee of the American Academy of Neurology. Neurology 56:1143-1153 (Pubitemid 32405708)
82. Shim YS, Morris JC (2011) Biomarkers predicting Alzheimer's disease in cognitively normal aging. J Clin Neurol 7:60-68
83. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE (2001) Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22:721-727 (Pubitemid 33055611)
84. Boissé L, Gill MJ, Power C (2008) HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 26:799-819 (Pubitemid 352037443)
85. Mattson MP, Haughey NJ, Nath A (2005) Cell death in HIV dementia cell death. Differ 12:893-904
86. Gartner S (2000) HIV infection and dementia. Science 287:602-604 (Pubitemid 30070897)
87. Ghafouri M, Amini S, Khalili K, Sawaya B (2006) HIV-1 associated dementia: symptoms and causes. Retrovirology 3:28
88. Nath A (2002) Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 186(Suppl 2):S193-S198 (Pubitemid 35370481)
89. Sacktor N, Haughey N, Cutler R, Tamara A, Turchan J, Pardo C, Vargas D, Nath A (2004) Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol 157:176-184 (Pubitemid 39576652)
90. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, Turchan J, Nath A, Mattson MP (2004) Perturbation of sphingolipid metabolism and ceramide production in HIVdementia. Ann Neurol 55:257-267 (Pubitemid 38167003)
91. Jana A, Pahan K (2004) Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci 24:9531
92. Williams R, Dhillon NK, Hegde ST, Yao H, Peng F, Callen S, Chebloune Y, Davis RL, Buch SJ (2009) Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia 57:734-743
93. Brabers NACH, Nottet HSLM (2006) Role of the pro-inflammatory cytokines TNF-α and IL-1β in HIV-associated dementia. Eur J Clin Invest 36:447-458 (Pubitemid 43876125)
94. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, Dawson TM, Dawson VL (1996) Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274:1917-1921 (Pubitemid 26424773)
95. Wesselingh SL, Takahashi K, Glass JD, McArthur JC, Griffin JW, Griffin DE (1997) Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. J Neuroimmunol 74:1-8 (Pubitemid 27128971)
96. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D (2004) Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363:1491-1502
97. Chambers BR, Donnan GA (2005) Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev:CD001923
98. Fisher M, Paganini-Hill A, Martin A, Cosgrove M, Toole JF, Barnett HJM, Norris J (2005) Carotid plaque pathology. Stroke 36:253-257
99. Stoll G, Bendszus M (2006) Inflammation and atherosclerosis. Stroke 37:1923-1932
100. Shah PK (2003) Mechanisms of plaque vulnerability and rupture. J Amer Coll Cardiol 41:S15-S22
101. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503 (Pubitemid 24379627)
102. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS (1990) Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem 265:22453-22459 (Pubitemid 120014322)
103. Windler E, Havel RJ (1985) Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 26:556-565 (Pubitemid 15073727)
104. Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF, Chatterjee S (2004) Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. ATVB 24:264-269 (Pubitemid 38202189)
105. Augé N, Maupas-Schwalm F, Elbaz M, Thiers JC, Waysbort A, Itohara S, Krell HW, Salvayre R, Nègre-Salvayre A (2004) Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 110:571-578 (Pubitemid 39031175)
106. Tellier E, Nègre-Salvayre A, Bocquet B, Itohara S, Hannun YA, Salvayre R, Augé N (2007) Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway. Mol Cell Biol 27:2997-3007 (Pubitemid 46581313)
107. Coatrieux C, Sanson M, Negre-Salvayre A, Parini A, Hannun Y, Itohara S, Salvayre R, Auge N (2007) MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radic Biol Med 43:80-89 (Pubitemid 46874846)
108. Augé N, Nikolova-Karakashian M, Carpentier S, Parthasarathy S, Nègre-Salvayre A, Salvayre R, Merrill AH Jr, Levade T (1999) Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem 274:21533-21538
109. Heo SH, Cho CH, Kim HO, Jo YH, Yoon KS, Lee JH, Park JC, Park KC, Ahn TB, Chung KC et al (2011) Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol 7:69-76
110. Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249-1256 (Pubitemid 35373556)
111. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285:17442-17452
112. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel, T, Jahantigh MN, Lutgens E, et al. (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2:ra81
113. Kubota M, Narita K, Nakagomi T, Tamura A, Shimasaki H, Ueta N, Yoshida S (1996) Sphingomyelin changes in rat cerebral cortex during focal ischemia. Neurol Res 18:337-341 (Pubitemid 26292134)
114. Nakane M, Kubota M, Nakagomi T, Tamura A, Hisaki H, Shimasaki H, Ueta N (2000) Lethal forebrain ischemia stimulates sphingomyelin hydrolysis and ceramide generation in the gerbil hippocampus. Neurosci Lett 296:89-92
115. Hernandez OM, Discher DJ, Bishopric NH, Webster KA (2000) Rapid activation of neutral sphingomyelinase by hypoxiareoxygenation of cardiac myocytes. Circ Res 86:198-204 (Pubitemid 30086181)
116. Bielawska AE, Shapiro JP, Jiang L, Melkonyan HS, Piot C, Wolfe CL, Tomei LD, Hannun YA, Umansky SR (1997) Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 151:1257-1263 (Pubitemid 27479755)
117. Takahashi K, Ginis I, Nishioka R, Klimanis D, Barone FC, White RF, Chen Y, Hallenbeck JM (2004) Glucosylceramide synthase activity and ceramide levels are modulated during cerebral ischemia after ischemic preconditioning. J Cereb Blood Flow Metab 24:623-627 (Pubitemid 38725366)
118. Zhai ST, Liu GY, Xue F, Sun GP, Liang L, Chen W, Xu GD, Li JJ, Yang J, Liang TB (2009) Changes of sphingolipids profiles after ischemia-reperfusion injury in the rat liver. Chin Med J 122:3025-3031
119. Hernandez et al. (2000) Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res
120. Yu J, Novgorodov SA, Chudakova D, Zhu H, Bielawska A, Bielawski J, Obeid LM, Kindy MS, Gudz TI (2007) JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. J Biol Chem 282:25940-25949 (Pubitemid 47372813)
121. Zhang DX, Fryer RM, Hsu AK, Zou AP, Gross GJ, Campbell WB, Li PL (2001) Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol 96:267-274 (Pubitemid 32433061)
122. Feng Y, LeBlanc MH (2006) N-tosyl-L-phenylalanyl-chloromethyl ketone reduces ceramide during hypoxic-ischemic brain injury in newborn rat. Eur J Pharmacol 551:34-40 (Pubitemid 44648052)
123. Tian HP, Qiu TZ, Zhao J, Li LX, Guo J (2009) Sphingomyelinase-induced ceramide production stimulate calcium-independent JNK and PP2A activation following cerebral ischemia. Brain Inj 23:1073-1080
124. O'Brien NW, Gellings NM, Guo M, Barlow SB, Glembotski CC, Sabbadini RA (2003) Factor associated with neutral sphingomyelinase activation and its role in cardiac cell death. Circ Res 92:589-591 (Pubitemid 36417690)
125. Yoshimura S, Banno Y, Nakashima S, Hayashi K, Yamakawa H, Sawada M, Sakai N, Nozawa Y (1999) Inhibition of neutral sphingomyelinase activation and ceramide formation by glutathione in hypoxic PC12 cell death. J Neurochem 73:675-683 (Pubitemid 29339841)
126. Brooks KJ, Hargreaves I, Bhakoo K, Sellwood M, O'Brien F, Noone M, Sakata Y, Cady E, Wylezinska M, Thornton J et al (2002) Delayed hypothermia prevents decreases in N-acetylaspartate and reduced glutathione in the cerebral cortex of the neonatal pig following transient hypoxia-ischaemia. Neurochem Res 27:1599-1604 (Pubitemid 36020112)
127. Singh A, Lee KJ, Lee CY, Goldfarb RD, Tsan MF (1989) Relation between myocardial glutathione content and extent of ischemia-reperfusion injury. Circulation 80:1795-1804 (Pubitemid 20031711)
128. Blaustein A, Deneke SM, Stolz RI, Baxter D, Healey N, Fanburg BL (1989) Myocardial glutathione depletion impairs recovery after short periods of ischemia. Circulation 80:1449-1457 (Pubitemid 19282534)
129. Leichtweis S, Ji LL (2001) Glutathione deficiency intensifies ischaemia-reperfusion induced cardiac dysfunction and oxidative stress. Acta Physiol Scand 172:1-10 (Pubitemid 32862755)
130. Soeda S, Tsuji Y, Ochiai T, Mishima K, Iwasaki K, Fujiwara M, Yokomatsu T, Murano T, Shibuya S, Shimeno H (2004) Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress. Neurochem Int 45:619-626 (Pubitemid 38844882)
131. Feng Y, LeBlanc MH (2003) Treatment of hypoxic-ischemic brain injury in newborn rats with TPCK 3 h after hypoxia decreases caspase-9 activation and improves neuropathologic outcome. Dev Neurosci 25:34-40 (Pubitemid 36921048)
132. Jin J, Hou Q, Mullen TD, Zeidan YH, Bielawski J, Kraveka JM, Bielawska A, Obeid LM, Hannun YA, Hsu YT (2008) Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells. J Biol Chem 283:26509-26517
133. Bhuiyan MIH, Islam MN, Jung SY, Yoo HH, Lee YA, Jin C (2010) Involvement of ceramide in ischemic tolerance induced by preconditioning with sublethal oxygen-glucose deprivation in primary cultured cortical neurons of rats. Biol Pharm Bull 33:11-17
134. Liu J, Ginis I, Spatz M, Hallenbeck JM (2000) Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-αlpha and ceramide. Am J Physiol Cell Physiol 278:C144-C153 (Pubitemid 30101905)
135. Daido S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y, Kondo S (2004) Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 64:4286-4293 (Pubitemid 38802435)
136. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT et al (2008) Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 111:4716-4722
137. Demircan B, Dyer LM, Gerace M, Lobenhofer EK, Robertson KD, Brown KD (2009) Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer 48:83-97
138. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523-530 (Pubitemid 27211828)
139. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223; discussion 23-24
140. Sawada M, Nakashima S, Kiyono T, Nakagawa M, Yamada J, Yamakawa H, Banno Y, Shinoda J, Nishimura Y, Nozawa Y et al (2001) p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells. Oncogene 20:1368-1378 (Pubitemid 32269941)
141. Sawada M, Kiyono T, Nakashima S, Shinoda J, Naganawa T, Hara S, Iwama T, Sakai N (2004) Molecular mechanisms of TNF-αlpha-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ 11:997-1008 (Pubitemid 39232359)
142. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS (2004) p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 23:1283-1290 (Pubitemid 38297183)